Stryker Reports Strong Q2 Earnings Amid Recovery from Cybersecurity Incident
Stryker Corporation (NYSE:SYK) reported strong second-quarter results in 2026, with organic sales growth of 9% and adjusted earnings per share rising by 17.9% year-over-year to $3.69. The company's MedSurg and Neurotechnology & Orthopaedics segments both delivered high-single-digit organic growth as operations recovered from a cybersecurity incident earlier in the year. Despite challenges, including a Peripheral Vascular supply disruption that caused a 6.7% decline in U.S. vascular sales, Stryker maintained confidence for recovery later in the year and raised its full-year outlook to an adjusted EPS range of $14.95–$15.10 with organic growth between 8.3% and 9.3%. The company also plans to resume share repurchases while prioritizing acquisitions as a capital allocation strategy. Chairman and CEO Kevin Lobo highlighted strong demand for hospital capital products, production increases, and commercial execution that contributed to the regained momentum in Q2.
Tickers: $SYK
Topics: capital_allocation cybersecurity_recovery medical_devices organic_growth